Hamann et al presented in the August issue of the journal their survey into the availability and use of Intralipid (intravenous fat emulsion) in England and Wales.1 That their survey is the fourth to be conducted on patterns of Intralipid uptake into clinical practice over the past 2 years speaks to the volume of interest in this new intervention, while the fact that it is the first to examine how, where and for what it is being used should give us poise.

The authors found that, while a significant number of hospitals had chosen to stock Intralipid, this uptake was not uniform within institutions, highlighting a differential adoption of Intralipid across the specialities. This may in part be explained by differing views on …